Indian Panel Seeks “Robust” Clinical Regulatory System To Fix Flaws
This article was originally published in PharmAsia News
Executive Summary
Under fire for lax clinical trial procedures, India’s government appointed a panel to review the system, which is proposing sweeping changes to get regulators, clinicians, patients and drug companies on the same page in the world’s second-most populous nation.